Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Not one, but two positive news items out today

<< Previous

Bullboard Posts

Next >>

Comment by venture009on Oct 24, 2023 2:58pm

135 Views

Post# 35698752

RE:RE:RE:RE:RE:RE:RE:RE:RE:Not one, but two positive news items out today

ONCInvestor I echo your sentiments. Because of past events, I currently have this sick feeling that we are in for more disappointments. I firmly believe we will not see any meaningful sp movement unless we get an AA or a buyout. Partnership will help for sure but not give us the movement we are all hoping for.

<< Previous

Bullboard Posts

Next >>

Three micro-cap value stocks trading at peak pessimism